Stanley Goldstein, MD
Allergy & Immunology · Rockville Centre, NYNPI 1548343304
Payments from drug & device makers
Across 1,062 payments — averaging $615.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$226K
- Regeneron Healthcare Solutions, Inc.$130K
- Genentech USA, Inc.$119K
- Sanofi$62K
- AstraZeneca$29K
- Novartis$19K
- plus $68K from 32 others
Across 3 payments — averaging $1469.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
- Amgen$274
What the payments were for
- Consulting fees$53,1658%
- Speaking & faculty fees$494,69877%
- Travel & lodging$68,03311%
- Food & beverage$26,6924%
- Education$8880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 248 | $226,305 |
| Regeneron Healthcare Solutions, Inc. | 189 | $129,713 |
| Genentech USA, Inc. | 148 | $119,330 |
| Sanofi | 105 | $62,124 |
| AstraZeneca | 81 | $28,865 |
| Novartis | 39 | $19,185 |
| Optinose US, Inc. | 33 | $13,924 |
| Amgen(2 entities) | 30 | $13,061 |
| Regeneron | 13 | $12,674 |
| Alk-abello, Inc | 31 | $11,659 |
| Boehringer Ingelheim International GmbH | 6 | $8,031 |
| Lilly USA, LLC | 14 | $3,418 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $1,800 |
| Kaleo, Inc. | 28 | $504 |
| Aimmune Therapeutics, Inc. | 14 | $335 |
| Sanofi-aventis U.S. LLC | 4 | $282 |
| Genentech, Inc. | 5 | $230 |
| Pfizer | 11 | $212 |
| Merck | 4 | $174 |
| Boehringer Ingelheim | 8 | $173 |
| Pharming Healthcare, Inc. | 3 | $164 |
| Teva Pharmaceuticals USA, Inc. | 8 | $158 |
| Shire North American Group Inc | 1 | $125 |
| Grifols USA, LLC | 6 | $114 |
| LEO Pharma Inc. | 5 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $83 |
| AbbVie | 4 | $80 |
| Biocryst US Sales Co., LLC | 3 | $64 |
| Octapharma USA, Inc. | 2 | $37 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| USWM, LLC | 2 | $32 |
| Mylan Specialty L.p. | 2 | $32 |
| Phadia US Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Aytu Biopharma, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Incyte Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$653,137 in reported general payments places this provider in the 95th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 22 | $108,234 |
| XolairOmalizumab | 11 | $28,518 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $23,664 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $19,995 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $11,819 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,773 |
| Arnuity ElliptaFluticasone Furoate | 21 | $7,187 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,381 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $4,284 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 12 | $2,848 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $2,326 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,317 |
| Epinephrine | 13 | $2,149 |
| Fluticasone Propionate | 63 | $1,716 |
| Azelastine Hcl | 16 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $226,305 | $50,84567 claims |
| Genentech, Inc.Xolair | $230 | $28,51811 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $28,865 | $19,59234 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $2,14913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in Rockville Centre
- Ellen EpsteinRockville Centre$63K
- Peter DeaneRochester$3.7M
- Syed MustafaRochester$3.6M
- Golda HudesBronx$2.4M
- Arye RubinsteinBronx$1.1M
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$980K
- Mili ShumWest Harrison$924K
- Paula BusseNew York$821K
- Gregory PuglisiPlainview$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.